The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies

Jie Xu 1,2, Lin Li 1, Pengfei Shi 1,2, Hongjuan Cui 1,2,* and Liqun Yang 1,2,*

1 State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, China; xujiesw@sina.com (J.X.); lilin1591905507@126.com (L.L.); spf2019@sina.cn (P.S.)
2 Cancer Center, Medical Research Institute, Southwest University, Chongqing 400716, China
* Correspondence: hcui@swu.edu.cn (H.C.); cysylq@swu.edu.cn (L.Y.)

Abstract: B-cell-specific Moloney murine leukemia virus integration region 1 (Bmi-1, also known as RNF51 or PCGF4) is one of the important members of the PcG gene family, and is involved in regulating cell proliferation, differentiation and senescence, and maintaining the self-renewal of stem cells. Many studies in recent years have emphasized the role of Bmi-1 in the occurrence and development of tumors. In fact, Bmi-1 has multiple functions in cancer biology and is closely related to many classical molecules, including Akt, c-MYC, Pten, etc. This review summarizes the regulatory mechanisms of Bmi-1 in multiple pathways, and the interaction of Bmi-1 with noncoding RNAs. In particular, we focus on the pathological processes of Bmi-1 in cancer, and explore the clinical relevance of Bmi-1 in cancer biomarkers and prognosis, as well as its implications for chemoresistance and radioresistance. In conclusion, we summarize the role of Bmi-1 in tumor progression, reveal the pathophysiological process and molecular mechanism of Bmi-1 in tumors, and provide useful information for tumor diagnosis, treatment, and prognosis.

Keywords: Bmi-1; miRNAs; tumorigenesis; chemoresistance; cancer therapy; molecular mechanism

1. Introduction

Polycomb group (PcG) proteins are a group of transcriptional inhibitors that regulate targeted genes at the chromatin level. They also play a critical role in embryonic development, cell proliferation, and tumorigenesis [1,2]. PcG proteins act on the development of organisms by forming two multimeric protein complexes: the polycomb repressive complex 1 (PRC1) and the polycomb repressive complex 2 (PRC2) [3]. B-cell-specific Moloney murine leukemia virus integration region 1 (Bmi-1, also known as RNF51 or PCGF4) is one of the core members of the PRC1 complex. This complex, acting through chromatin remodeling, is an essential epigenetic repressor involved in embryonic development and self-renewal in somatic stem cells [4–6]. Therefore, Bmi-1 also is an oncogene, and its abnormal expression is associated with tumorigenesis and drug resistance in many cancers, including bladder cancer cells, B-cell lymphoma cells, melanoma cells, and others. Non-coding RNAs (ncRNAs) are a class of RNAs produced in noncoding regions that are not translated into proteins but are widely expressed in organisms [7]. With the development of gene sequencing technology, increasing evidence suggests that ncRNAs have crucial biological functions and play core roles in regulating gene expression [8]. In recent years, it has been identified that microRNAs (miRNAs) play important roles in various biological processes by inhibiting the translation of mRNAs and inducing their degradation, which makes them potential molecular targets for cancer therapy [9–13]. Interestingly, several recent studies have found that Bmi-1 is targeted and regulated by many miRNAs in cancer. Furthermore, the unique biological functions and cancer-promoting effects of Bmi-1 have also attracted increased attention. Therefore, in this review, we first describe the normal function of Bmi-1; then, we review the relevant signaling pathways regulated by Bmi-1 in...
normal and carcinogenic conditions and its regulatory network with miRNAs, to provide a reference for a more comprehensive understanding of the role of Bmi-1 in cancer.

2. Molecular Features and Characteristics of Bmi-1

The structure of Bmi-1 in humans and mice is very similar, and the homologies of DNA and amino acid in Bmi-1 are 86% and 98%, respectively. The Bmi-1 gene in humans, composed of 10 exons and 9 introns, is localized on the short arm of chromosome 10 (10p11.23). The Bmi-1 protein is 37 kD in size, consists of 326 amino acids, and has a highly conserved structure. There are several important structures in the amino acid sequence of Bmi-1 protein. The N-terminal is a RING finger domain, which is composed of a zinc finger and C3hC4 sequence. Bmi-1 can regulate transcription, affect cell proliferation, and participate in the formation of the malignant tumors by RING finger binding to other critical proteins. The helix–turn–helix structure (HTH structure) is located in the center of the Bmi-1 protein, and mediates the transcriptional inhibition of Bmi-1 by binding with DNA. At the carboxyl terminus, the PEST structure of the PEST region situated at the C terminal contains many serine, glutamic acid, threonine, and proline residues [14], which are associated with intracellular turnover of Bmi-1 protein. Two nuclear localization signals (NLS1, NLS2) are contained in Bmi-1, of which NLS2 is required for Bmi-1 localization in the nucleus. Figure 1 illustrates the structure of the Bmi-1 gene and Bmi-1 protein, the illustration is redrawn (with modifications) from Sahasrabuddhe (2016) [15].

![Figure 1](image_url)

**Figure 1.** The structure of gene and protein of Bmi-1. The Bmi-1 gene contains 10 exons and 9 introns. The amino acid sequence of Bmi-1 protein contains a RING finger domain, a helix–turn–helix, two nuclear localization signals (NLS), and a PEST region.

3. Upstream Regulatory Mechanisms of Bmi-1

Bmi-1 is expressed in almost every human tissue and in many cancers, and serves as a biomarker for some cancers. Therefore, it is crucial to explore the mechanisms that regulate Bmi-1 mRNA and Bmi-1 protein levels. Over the past decade, researchers have made some progress in the regulation of Bmi-1 at the transcriptional, post-transcriptional, and post-translational levels. It is currently known that Bmi-1 is included in the positive or negative transcriptional regulation of many transcription factors. Positively regulated transcription factors are Sp1, Twist1, FoxM1, ZEB1, E2F1, SALL4, MYC-N, c-MYC, and HDACs, while negatively regulated transcription factors are Mel18, Nanog, and KLF4 [15].

Post-translational modifications (PTMs) of proteins are an important part of proteomics. Proteins change their spatial conformation, activity, stability, and interaction performance with other molecules through PTMs, thereby participating in the regulation of various life activities in the body. Most proteins can undergo PTMs, and there are more than 200 known covalent modifications of proteins, including phosphorylation, nitrosy-
lation, nitration, ubiquitination, and sumoylation, among others. PTMs are associated with many important diseases, including cancer. There have been some studies on the post-translational modification of Bmi-1. Bmi-1 can be activated by phosphorylation. For example, the state of Bmi-1 protein binding to chromosomes is related to its phosphorylation; in G1/S phase, non-phosphorylated Bmi-1 specifically binds to chromosomes, while in G2/M phase, phosphorylated Bmi-1 does not bind to chromosomes [16]. Bmi-1 represses the expression of the Ink4a-Arf locus, which encodes two tumor suppressor genes, p16$^{\text{ink4a}}$ and p19$^{\text{Arf}}$. Bmi-1 is phosphorylated (and inactivated) at Ser 316 by Akt serine/threonine kinase, also known as protein kinase B (PKB), to promote p16$^{\text{ink4a}}$ and p19$^{\text{Arf}}$ expression and inhibit hematopoietic stem cell self-renewal [17]. Similarly, the Wnt5a-ROR1 complex can phosphorylate Bmi-1 through the Akt pathway to promote tumorigenesis [18]. It has also been reported that activation or overexpression of MAPKAP kinase 3 leads to the phosphorylation of Bmi-1 and other PcG members, and promotes their dissociation from chromatin [19]. Sumoylation is a reversible post-translational modification which has emerged as a crucial molecular regulatory mechanism, involved in the regulation of replication, cell-cycle progression, protein transport and the DNA damage response. The study found that DNA damage can induce the sumoylation of lysine 88 in Bmi-1, and knockout of chromobox 4 (CBX4), a member of the polycomb group family of epigenetic regulatory factors, can eliminate this phenomenon, which means that CBX4 can mediate the sumoylation of Bmi-1 [20]. Moreover, p53/p21 can inversely regulate Bmi-1 expression by affecting ubiquitin/proteasome activity [21]. This also implies that Bmi-1 may be ubiquitinated. Furthermore, Ser255 was found to be the site of O-GlcNAcylation of Bmi-1 in prostate cancer, and O-GlcNAcylation of Bmi-1 promoted the stability of Bmi-1 protein and its oncogenic activity [22].

MicroRNAs (miRNAs or miRs) are a class of small of ncRNAs that contain about 19–24 nt. Although miRNAs do not encode proteins, they regulate the expression levels of some genes at the post-transcriptional stage. MiRNAs negatively regulate the expression of target genes by complete or incomplete complementary binding to the 3′-UTR of target mRNAs, promoting the degradation or translational repression of target mRNAs. There is growing evidence that miRNAs are involved in essential biological processes, including development, differentiation, proliferation, apoptosis, invasion, and metastasis. The 3′UTR length of Bmi-1 is 2090 nt. The miRNAs mainly target two spacers of the 3′UTR of Bmi-1. The first target position is 469–725, which includes miR-128, miR-221, miR-183, and miR-200b/c; the other position is 1442–1758, including miR-203, miR-218. We summarize the interaction between Bmi-1 and miRNAs in human tumors in Table 1, to provide information for further research on cancer treatment and clinical applications.

### Table 1. MicroRNAs that inhibit Bmi-1 in tumors.

| miRNAs | Efficacy for Cancer | Cancer Type | References |
|--------|--------------------|-------------|------------|
| miR-34a, miR-15a, miR-218, miR-183, miR-498, miR-128 | Inhibits proliferation; inhibits metastasis; decreases chemoresistance | Gastric cancer | [23–27] |
| miR-218, miR-200c, miR-485-5p | Inhibits proliferation; inhibits migration; increases apoptosis | | |
| miR-15a, miR-183 | Inhibits proliferation and EMT | | |
| miR-203 | Inhibits self-renewal | Pancreatic ductal adenocarcinoma | [31,32] |
| miR-203 | Promotes apoptosis | Esophageal cancer | [33] |
| miR-218, miR-203 | Inhibits proliferation and invasion; introduces apoptosis; decreases radiosensitivity and chemosensitivity | Hepatocellular carcinoma | [35–39] |
| miR-218 | Increases chemosensitivity | Liver cancer | [38] |
| miR-320a | Inhibits proliferation and migration | Nasopharyngeal carcinoma | [40] |
Table 1. Cont.

| miRNAs                | Efficacy for Cancer                                         | Cancer Type        | References    |
|-----------------------|------------------------------------------------------------|--------------------|---------------|
| miR-132, miR-498      | Increases radiosensitivity; inhibits proliferation and invasion | Cervical cancer    | [41,42]       |
| miR-128, miR-200b, miR-221, miR-30d, miR-15a, miR-330-3p, miR-212 | Inhibits proliferation and migration; increases chemosensitivity | Prostate cancer    | [43–50]       |
| miR-200c, miR-194     | Inhibits proliferation; inhibits EMT                       | Endometrial carcinoma | [51,52]      |
| miR-128, miR-495      | Inhibits proliferation; introduces apoptosis; increases chemosensitivity and DNA damage | Breast cancer       | [53,54]       |
| miR-132, miR-15a, miR-16, miR-128 | Inhibits metastasis; increases chemosensitivity | Ovarian cancer     | [55–57]       |
| miR-361-5p, miR-218, miR-128 | Inhibits proliferation; inhibits EMT                   | Glioma             | [58–60]       |
| miR-128, miR-16, miR-128a | Introduces radiosensitivity; inhibits proliferation and angiogenesis | Glioblastoma       | [61–63]       |
| miR-128a              | Inhibits proliferation, inhibits metastasis, inhibits apoptosis | Medulloblastoma    | [64]          |
| miR-200c, miR-139-5p, miR-218, miR-15 | Inhibits proliferation; inhibits metastasis; inhibits apoptosis; inhibits autophagy | Osteosarcoma       | [65,66]       |
| miR-218               | Inhibits ROS                                               | Bladder cancer     | [13,67–69]    |
| miR-218               | Inhibits proliferation and metastasis                      | Acute Promyelocytic Leukemia | [70]         |
| miR-218               | Inhibits proliferation and metastasis                      | Lung adenocarcinoma | [71]          |
| miR-203               | Inhibits proliferation                                     | Myeloma            | [72]          |
| miR-200C              | Inhibits proliferation and metastasis                      | Renal cancer       | [73]          |
| miR-154               | Inhibits proliferation and migration                       | Non-small cell lung cancer | [74]         |
| miR-200c              | Inhibits proliferation and migration; increases chemosensitivity | Melanoma           | [75]          |

4. Bmi-1-Targeted Processes in Cancer

Bmi-1 protein belongs to the polycomb family of transcriptional repressors, and binds to polycomb response elements in the genome to silence the transcription of specific target genes. The genes to be transcriptionally regulated by Bmi-1 include INK4a/ARF, Pt, homeobox protein HoxC13, human telomerase reverse transcriptase (hTERT), etc. [76–79]. Figure 2 illustrates the downstream genes directly regulated by Bmi-1. In addition, Bmi-1 is involved in many classical signaling pathways, for example mTOR, NF-kB, PI3K/Akt, and other signaling pathways. The function of Bmi-1 in tumors has been identified in various pathological processes, including abnormal cell proliferation, evasion of apoptosis, migration of cancer cells, and stemness maintenance of cancer stem cells (CSCs). Therefore, we provide a corresponding review of the key target genes and signaling pathways behind these processes.

4.1. Bmi-1 in Cancer Proliferation

Hyperproliferation is a typical feature of cancer progression, manifested by altered expression and activity of cell cycle-related proteins. The most classic downstream target of Bmi-1 is INK4a/ARF. The tumor suppressor gene INK4a/ARF can encode two regulatory genes: p16<sup>INK4a</sup> and p14<sup>ARF</sup> (p19<sup>ARF</sup> in mice). Their normal and orderly expression is the key to maintaining the balance of the cell cycle. On the one hand, p16<sup>INK4a</sup> arrests cells in the G<sub>0</sub>/G<sub>1</sub> phase through cyclinD-CDK4/6-pRb-E2F. Mechanistically, when Bmi-1 is deficient, p16<sup>INK4a</sup> is up-regulated, which prevents the binding of CDK4/6 to cyclinD, leading to phosphorylation of Rb. Phosphorylated Rb binds to E2F transcription factor to inhibit E2F transcription-factor-mediated transcription, which arrests the cell cycle in the G0/G1 phase [76]. On the other hand, p14<sup>ARF</sup> regulates the cell cycle through the
MDM2/p53 pathway [15,84–87]. In detail, the p14ARF (p19ARF) protein can antagonize the ubiquitin-protein ligase MDM2 and p53-dependent transcription, thereby stabilizing tumor protein p53, causing cell apoptosis [15,84–87]. Bmi-1-shRNA reduces the expression of cyclin D1 and increases the expression of cyclin dependent kinase inhibitor p21 and p27 through the p16INK4a independent pathway, to arrest lung adenocarcinoma cells in the G0/G1 phase [88]. USP22, an oncogene, could actively and effectively participate in the regulation of the cell cycle through the INK4a/ARF signaling pathway mediated by Bmi-1 in human colorectal cancer cells [89]. Similar phenomena have also been detected in gallbladder carcinoma, HeLa cells, lung cancer, esophageal carcinoma cell, etc. [90–93]. Bmi-1 can also activate the PI3K/mTOR/4EBP1 signaling pathway in ovarian cancer cells to regulate cell proliferation [94]. N-acetylglucosamine transferase (OGT) is the only known enzyme to catalyze the O-GlcNAcylation in humans. O-GlcNAcylation can promote the stability and oncogenic activity of Bmi-1 [22]. MiR-485-5p can regulate the O-GlcNAcylation level and the stability of Bmi-1 by inhibiting OGT, and then inhibit the proliferation of colorectal cancer cells [28]. Nevertheless, some studies have shown that Bmi-1 does not affect the cell cycle of lung cancer cells and the expression of p16/p19, PTEN, Akt, or p-Akt [95]. This may be related to cell type.

4.2. Bmi-1 in Cancer Apoptosis

Strong anti-apoptotic ability is one of the characteristics of cancer cells. Bmi-1 directly and indirectly regulates cell apoptosis via various pathways. The first pathway is the p14ARF/MDM2/p53 signal pathway mentioned above. Inhibition of Bmi-1 can promote the expression of p14ARF (p19ARF), and p14ARF (p19ARF) can antagonize the ubiquitin-protein ligase MDM2 to stabilize p53 and cause apoptosis. This phenomenon has been reported in many studies [29,96,97]. A second pathway involves the inhibition of Bmi-1, causing abnormal mitochondrial function and increasing the level of ROS, leading to apoptosis. For example, a recent study found that sodium butyrate induced ROS-mediated apoptosis by inhibiting the expression of Bmi-1 through miR-139-5p [13]. The third pathway is the Bmi-1 regulation of cell apoptosis by the NF-κB pathway. Expression of Bmi-1 could protect glioma cells from apoptosis by activating the NF-κB pathway [98]. Consistently, overexpression of Bmi-1 can increase cisplatin-induced apoptosis resistance in osteosarcoma by activating the NF-κB signal pathway [99]. In addition, the loss of Bmi-1 leads to impaired repair of DNA double-strand breaks by homologous recombination, ultimately leading to apoptosis [96]. Inhibition of Bmi-1 reduces the ubiquitination of myeloid cell leukemia sequence 1 (Mcl-1) by downregulating deubiquitinating enzyme (DUB3), resulting in cancer cell apoptosis [99].

4.3. Bmi-1 in Cancer Autophagy

Autophagy is a conserved self-degradation system that is critical for maintaining cellular homeostasis during stress conditions. Autophagy plays a dichotomous role in cancer by suppressing benign tumor growth but promoting advanced cancer growth [100]. Bmi-1 also affects cellular autophagy generally through PI3K/Akt and AMPK signaling pathways. Knockdown of Bmi-1 induced autophagy in ovarian cancer cells via ATP depletion [101]. Sodium butyrate induced AMPK/mTOR pathway-dependent autophagy via the miR-139-5p/Bmi-1 axis in human bladder cancer cells [13]. Knockdown of Bmi-1 in breast cancer cells also induced autophagy [102,103]. Additionally, betulinic acid induced autophagy and apoptosis in bladder cancer cells through the Bmi-1/ROS/AMPK/mTOR/ULK1 axis [86]. Similarly, Bmi-1 overexpression promoted migration and proliferation of cardiac fibroblasts by regulating the Pten/PI3K/Akt/mTOR signaling pathway [104]. In addition, the expression of Bmi-1 targets the inhibition of cyclinG2 expression, and cyclinG2 acts by disrupting the phosphatase 2A complex, which activates the PKCc/AMPK/JNK/ERK pathway involved in autophagy [105].
Figure 2. Downstream genes directly regulated by Bmi-1. Bmi-1 can enhance H2A ubiquitination and bind to the promoter of HoxC13 to reduce the expression of HoxC13 in HeLa cells [77]. The most classic downstream target of Bmi-1 is INK4a/ARF. The tumor suppressor gene INK4a/ARF can encode two regulatory genes: p16INK4a and p14ARF (p19ARF in mice). P16INK4a arrests cells in G0/G1 phase through cyclinD-CDK4/6-pRb-E2F. p14ARF regulates the cell apoptosis through MDM2-p53 pathway [76]. Bmi-1 can regulate the development of colon cancer by negatively regulating the expression level of PTEN and then activating the Akt/GSK3β axis [78]. Bmi-1 regulates memory CD4 T cell survival via repression of the proapoptotic BH3-only protein Noxa gene [80]. Bmi-1 regulates cell fate via transcriptional repression tumor suppressor WW Domain Containing Oxidoreductase (WWOX) in small-cell lung cancer cells [81]. Bmi-1 suppresses the expression of Smgc gene and Gcnt3 gene [82]. Bmi-1 activates Wnt signaling in colon cancer by negatively regulating the Wnt antagonist IDAX [83]. Bmi-1 can also transcriptionally positively regulate human telomerase reverse transcriptase (hTERT) to block senescence in human mammary epithelial cells [79].

4.4. Bmi-1 in Cancer EMT

Cancer cells have the characteristics of invasion into surrounding tissues and metastasis to distant tissues, and they continue to grow in these organs, destroying the function of the organs, and finally causing the death of the patient. The expression of Bmi-1 is closely related to tumor migration and invasion [93,95,106–109]. It has been reported that down-regulation of Bmi-1 reduces the migration and invasion of endometrial cancer cells in vivo and in vitro, by increasing the expression levels of E-cadherin and keratin, and down-regulating N-Cadherin, vimentin, and SLUG [106]. Likewise, Bmi-1 induces miR-27a and miR-155 to negatively regulate the expression of raf kinase inhibitory protein (RKIP), which promotes the migration and invasion of gastric cancer cells [107]. Additionally, Bmi-1 promotes the migration and invasion of Hepatocellular carcinoma by inhibiting phosphatase
and tensin homolog (PTEN) and activating the PI3K/Akt pathway, and increasing the expression of MMP2, MMP9 and VEGF [110]. Similar phenomena have also been found in breast cancer, colon cancer, esophageal cancer cells [107]. Moreover, Bmi-1 increases luciferase activity of the MMP9 promoter-driven reporter gene containing an NF-κB binding site, which promotes MMP9 transcription levels in glioma cells [111]. Bmi-1 may also regulate the TLR4/MD2/MyD88 complex-mediated NF-κB signaling pathway to participate in colorectal cancer cell EMT [112]. Furthermore, miR-218, miR-330-3p, and miR-498 may regulate the migration and invasion of cancer cells through the Bmi-1/Akt axis [112].

4.5. Bmi-1 in Cancer DNA Damage Response

An underlying feature of cancer is genomic instability, which is associated with the accumulation of DNA damage. Bmi-1 plays an important role in the regulation of DNA damage response (DDR) [113,114]. The lack of Bmi-1 in cells could cause mitochondrial dysfunction, and at the same time, the DDR pathway could be initiated with the increase of ROS [115]. Bmi-1 enhances the repair of damaged DNA through epigenetic mechanisms to reduce the genotoxic effects of ionizing radiation (IR) [116]. Bmi-1 is a component of PRC1, and affects the expression of many genes through histone H2A ubiquitination. Mechanically, Bmi-1 binds to ring2/ring1b subunit to form a functional E3 ubiquitin ligase, and inhibits the expression of multiple gene through monoubiquitination of histone H2A in lysine 119 [117]. Through Bmi-1/RIN1b E3 ubiquitin ligase, Bmi-1 promotes histone H2A and γH2AX ubiquitination for the repair of double-stranded DNA breaks by stimulating homologous recombination and non-homologous end connection [117,118]. In addition, the knockout of Bmi-1 further aggravated the phosphorylation of checkpoint kinase 2 (Chk2) and H2AX induced by cisplatin treatment [119].

4.6. Bmi-1 in Cancer Inflammation

Inflammation is often associated with the progression of cancer. Cells responsible for cancer-related inflammation are genetically stable and therefore do not rapidly emerge drug resistance. Therefore, targeting inflammation is an attractive strategy for both cancer prevention and cancer therapy [120]. NF-κB transcription factors are major mediators of inflammatory processes and key players in innate and adaptive immune responses. Therefore, NF-κB pathway has been considered as the target of anti-inflammatory drugs. Recent studies have found that Bmi-1 is involved in the regulation of NF-κB signaling pathway. For example, Bmi-1 promotes tumor proliferation, metastasis and drug resistance by activating NF-κB signaling pathway [121]. Similarly, Bmi-1 promotes glioma invasion by activating NF-κB/MMP3 or NF-κB/MMP9 signaling pathways [111,122]. Moreover, Bmi-1 promote colorectal cancer migration and EMT in an inflammatory microenvironment by regulating TLR4/MD2/MyD88 complex-mediated NF-κB signaling pathway [112]. Furthermore, the expression of Bmi-1 can activate the NF-κB signaling pathway and increase the expression of vascular endothelial growth factor C (VEGF-C)to promote glioma angiogenesis [123]. Additionally, toll-like receptor 4 (TLR4) promotes inflammation by inhibiting Bmi-1 to activate the NOD-like receptors (NLRs) family member (NLRP3) pathway [124].

4.7. Bmi-1 in Cancer Stem Cells

Stem cells have self-renewal ability, and produce at least one highly differentiated cell. Cancer stem cells refer to cancer cells with stem cell properties such as self-renewal and multicellular differentiation. At present, many studies have proved that CSCs are present in a variety of tumors, such as leukemia, breast cancer, lung cancer, glioblastoma, colon cancer, liver cancer, and others [125]. Increasing evidence has indicated that Bmi-1 plays a critical role in the self-renewal and differentiation of cancer stem cells [6,126].

Revealing the molecular mechanism of the self-renewal of neural stem cells (NSCs) is one of the main goals for understanding the homeostasis of the adult brain. Neural stem cells and progenitor cells (NSPC) strictly regulate self-renewal potential to maintain homeostasis in the brain. The researchers found that the absence of Bmi-1 led to the
decline of self-renewal ability in NSCs [127,128]. Molofsky et al. further found that Bmi-1 promoted the self-renewal of NSCs by inhibiting INK4a/ARF1. One study found that Bmi-1-knockout mice lacked stem cells and developed defects in the central nervous system, but no significant effect on the proliferation of progenitor cells was recorded. The results showed that Bmi-1 is a key factor for maintaining the stability of NSCs, but had little influence on differentiated cells [129,130]. Furthermore, Protein S (PROS1) can affect the self-renewal of adult hippocampal NSPC by down-regulating Bmi-1 [131]. In summary, Bmi-1 is a vital factor for the self-renewal of NSCs.

Bmi-1 also plays a pivotal role in hematopoietic stem cells (HSCs). Park et al. reported that Bmi-1 is strongly expressed in fetal mouse and adult human HSCs. Thus, Bmi-1 knockout resulted in the reduction of proliferation of mouse bone marrow, resulting in the death of most of the studied mice before adulthood [5]. Lessard et al. [132] found that the number of stem cells in peripheral leukemia cells from Bmi-1 wild-type mice was significantly higher than that in Bmi-1 knockout mice. Subsequently, they found a decrease of self-renewal ability of HSCs and poor hematopoiesis in Bmi-1−/− mice. Mice were then injected with fetal liver HSCs (Bmi-1+/+ or Bmi-1−/−) after high doses of lethal radiation. The results showed that the hematopoietic ability of bone marrow was dependent on the expression of Bmi-1.

In breast cancer stem cells (BCSCs), Bmi-1 is a target of the miR-200 family and miR-128 family. Furthermore, Bmi-1 is also regulated by certain signaling pathways, such as the Hedgehog and Wnt pathways. The Hedgehog signaling pathway promotes self-renewal in mammary stem cells and BCSCs by up-regulating Bmi-1 [4]. Bmi-1 can activate the Wnt signaling pathway by inhibiting Dickkopfs (DKK), a Wnt inhibitor gene. DKK1 resulted in the up-regulation of c-MYC, which further contributed to the transcriptional self-activation of Bmi-1 [133].

Bmi-1 is a regulator of self-renewal in prostate stem cells and a marker in intestinal stem cells [134,135]. Bmi-1 is also expressed in mesenchymal stem cells isolated from the umbilical cord [136]. Therefore, further regulatory mechanisms of Bmi-1-promoting CSC need to be revealed, and its role in tumor promotion requires exploration, to provide new therapeutic strategies for anti-tumor therapy.

4.8. Bmi-1 in Tumor Microenvironment

The tumor microenvironment (TME) comprises various cell types (endothelial cells, fibroblasts, immune cells, etc.) and extra-cellular components (cytokines, growth factors, hormones, extracellular matrix, etc.) that surround tumor cells and are nourished by a vascular network. Tumor cells interact with the surrounding cells through the circulatory and lymphatic systems to influence the progression of cancer and therapeutic efficacy of treatments [137,138]. The expression of Bmi-1 can also affect the tumor microenvironment (TME). Selective Bmi-1 inhibitor PTC-209 increases the expression of DKK1 by down-regulating Bmi-1, impairing in vitro osteoclast formation and destroying the tumor microenvironment [139]. There is a report that Bmi-1 is upregulated in multiple myeloma-associated macrophages (MM-MΦs) and that Bmi-1 modulates MM-MΦ’s pro-myeloma functions. Bmi-1 inhibitors could not only target multiple myeloma (MM) cells, but also eliminate MM-MΦs in the treatment of myeloma [140]. Another report suggests that tumor-associated macrophages (TAMs) may cause increased Bmi-1 expression through miR-30e suppression, leading to gastrointestinal cancer progression [141]. At present, there are few reports on the effect of Bmi-1 on the tumor microenvironment. Therefore, the role of Bmi-1 in the tumor microenvironment needs to be further explored.

5. Clinical Characteristics and Cancer Therapy of Bmi-1

5.1. Protein Expression and Clinical Characteristics of Bmi-1

In the past two decades, many researchers have discussed the relationship between the expression level of Bmi-1 and the clinical characteristics of different cancers. Although a few results are contradictory, most of the results prove the importance of Bmi-1 in the
occurrence and development of cancer. In order to describe it more simply and intuitively, we summarized the expression level and clinical characteristics of Bmi-1 in Table 2.

Table 2. Protein expression and clinical characteristics of Bmi-1.

| Cancer Type                          | mRNA/Protein | High/Low Expression | Positive Percentage | Clinical Characteristics                                                                 | Remarks                     | Ref. |
|--------------------------------------|--------------|---------------------|---------------------|------------------------------------------------------------------------------------------|-----------------------------|------|
| Gastric cancer                       | Protein      | High                | GC 162 (52.5%)      | Associated with Lauren's and Borrmann's classification and clinical stage                  | Mainly in nucleus           | [142]|
|                                       | mRNA         | High                | GC 178 (70.8%)      | Associated with sex, gross type, and histologic type                                       | Not involved                | [143]|
| Nonsmall cell lung cancer            | Protein and mRNA | High                | 71                  | Associated with tumor size, depth of invasion, lymph node metastasis, and clinical stage | Not involved                | [144]|
| Endometrial Carcinoma                | Protein      | High                | 48                  | A significant positive relationship between Bmi-1 and Ki-67, cyclin A, or p53              | Mainly in nucleus           | [145]|
| Esophageal cancer                    | Protein and mRNA | High                | 302 (55.3%)         | Correlated with clinical stage, lymph node metastasis, vascular invasion, and human papillomavirus (HPV) infection | Mainly in nucleus           | [146]|
| Cervical cancer                      | Protein and mRNA | High                | 203 (66.5%)         | Correlated with clinical stage, depth of invasion, nodal involvement, distant metastasis, and Ki67 level | Mainly in nucleus           | [147]|
| Acute myeloid leukemia (AML)         | mRNA         | High                | 60                  | Showed a strong association with failure to achieve complete remission (CR) or relapse     | Not involved                | [148]|
| Esophageal squamous cell carcinoma (ESCC) | Protein   | High                | 80 (78.7%)          | Correlated with depth of invasion and lymph node metastasis, but not with patient age, tumor size, or nationality | Not involved                | [149]|
| ESCC                                 | Protein and mRNA | High                | 171 (64.3%)         | Correlated with stage and PN classification.                                            | Mainly in nucleus           | [150]|
| Endometrial adenocarcinoma           | Protein      | High                | 60                  | Correlated with FIGO stage, myometrial invasion, and lymph node metastasis                | Both the nucleus and cytoplasm | [106]|
| Colon cancer                         | Protein and mRNA | High                | 203 (66.5%)         | Correlated with clinical stage, depth of invasion, nodal involvement, distant metastasis, and Ki67 level | Mainly in nucleus           | [151]|
| Uterine cervical cancer              | Protein      | High                | 152                 | Correlated with tumor size, clinical stage, and regional lymph node metastasis            | Mainly in nucleus           | [152]|
| Bladder cancer                       | Protein      | High                | 137                 | Correlated with histopathological classification, clinical stage, recurrence, and patient survival | Mainly in nucleus           | [153]|
| Ovarian carcinoma                    | Protein      | Low                 | 179                 | Correlated with tumors' histological type, grade, pT/pN/pM status, and FIGO stage         | Mainly in nucleus           | [154]|
| Epithelial ovarian carcinoma         | Protein      | High                | 40 (72.5%)          | Associated with advanced International Federation of Gynecology and Obstetrics stages, bilaterality, and higher Gynecologic Oncology Group grades and carcinomas of serous histology | Mainly in nucleus           | [155]|
| Uterine cervical cancer              | mRNA         | High                | 109                 | Correlated with clinical stage and lymph node metastasis                                  | Not involved                | [156]|
| Salivary adenoid cystic carcinoma    | Protein      | High                | 10                  | Associated with tumor metastasis, Snail, Slug, and E-cadherin, serves as a highrisk for AdCC | Not involved                | [157]|
| Laryngeal carcinoma                  | Protein      | High                | 64 (84.4%)          | Correlated with distant metastasis, N pathological status, T classification                | B oth the nucleus and cytoplasm | [158]|
| Pancreatic cancer                    | Protein      | High                | 72 (48.61%)         | Correlated with the presence of lymph node metastases and negatively correlated with patient survival rates | Mainly in nucleus           | [159]|
| Squamous cell carcinoma of the tongue | Protein      | High                | 73 (82%)            | Correlated with recurrence                                                                | in nucleus                  | [160]|
| ovarian Carcinoma                    | mRNA         | High                | 47 (72.34%)         | Correlated with tumor grade                                                                | Both the nucleus and cytoplasm | [161]|
| Neuroblastoma                        | Protein      | High                | 45                  | Correlated with MYCN                                                                      | Not involved                | [162]|
| Pediatric brain tumors               | mRNA         | High                | 56                  | Expression of Bmi-1 showed significant differences between high-grade tumors and low-grade tumors | Not involved                | [163]|


5.2. Bmi-1 in Chemoresistance and Cancer Therapy

Radiation and chemotherapy are common treatments for cancer. Drug resistance is one of the main obstacles to effective anticancer treatment. Many clinical data have reported that Bmi-1 is related to the drug resistance of tumors [114,164–167]. Silencing Bmi-1 could enhance camptothecin-induced DNA double-strand breaks and promote camptothecin-induced apoptosis. Conversely, increasing Bmi-1 can significantly reduce camptothecin-induced apoptosis [168]. Direct inhibition of Bmi-1 abrogates head and neck cancer stem-cell self-renewal and increases tumor sensitivity to cisplatin [169]. Hypoxic exposure regulates PI3K/Akt signal and EMT through activation of the HIF-1α/Bmi-1 signal to induce LSCs drug resistance [170]. Similarly, Bmi-1 activates the PI3K/Akt pathway and NF–κB pathway to promote cell growth and resistance to cisplatin treatment [170]. Furthermore, the low expression of Survivin is considered to be one of the factors for the success of chemotherapy; Bmi-1 promotes the drug resistance of B-cell lymphoma cells through the regulation of Survivin [171]. Although radiation therapy is one of the main methods of cancer treatment, tumors often acquire radioresistance, which leads to radiotherapy failure. Bmi-1 depletion makes radiation-resistant ESCC cells sensitive to radiotherapy by inducing apoptosis, senescence, ROS production, and oxidase gene expression (Lpo, Noxo1 and Alox15), reducing DNA repair capabilities [172]. Interestingly, the inhibition of Bmi-1 activates immune responses in tumor cells and recruits CD8+ T cells. Mechanistically, knockdown of Bmi-1 not only eliminated CSCs, but also sensitized tumor cells to anti-PD-1 antibodies by recruiting CD8+ T cells [173]. In conclusion, Bmi-1 has development potential as a target for the treatment of cancer. Perhaps in future the development of small-molecule compounds that effectively target Bmi-1 will be an option for anticancer drug development.

At present, certain small molecule inhibitors of Bmi-1 have been studied, and the most commonly used small molecule inhibitor of Bmi-1 is PTC-209. An article published in 2013 reported that researchers had identified a low molecular compound PTC-209 for the first time. They also found that PTC-209 reduced the tumorigenic activity and volume of xenograft tumors and the number of functional colorectal cancer-initiating cells in mice, after short-term treatment [174]. Subsequently, the drug has also been studied in other cancer cells and has demonstrated its anti-tumor effect, including for head neck squamous cell carcinoma (HNSCC) [175], prostate cancer [176], myeloma [177], glioblastoma [178], and cervical cancer cells [179]. In 2019, researchers developed an orally active nanoparticle PTC-209 vector, which can significantly inhibit colony formation and migration of colon cancer cells, and inhibit tumor progression and metastasis in orthotopic tumor-bearing mice by reversing stemness [180]. An orally active and selective Bmi-1 inhibitor, PTC-596, downregulated bcl2 family apoptosis regulator Mcl-1 and induces p53-independent mitochondrial apoptosis in AML progenitor cells [181]. The drug has also been explored for treatment of other cancers, for example, mantle cell lymphoma [182], cancer stem-like cells [99], multiple myeloma [183], and glioblastoma multiforme [184]. PTC-596 has been used in clinical phase 1 for conditions including diffuse intrinsic pontine glioma and leiomyosarcoma [185,186]. Moreover, a novel inhibitor, RU-A1, was developed based on the RNA three-dimensional (3D) structure of Bmi-1 and showed stronger potency than PTC-209 in targeting CSCs [187]. PTC-028, an orally bioavailable compound, mediates hyperphosphorylation of Bmi-1 accompanied by a transient decrease in ATP and disruption of mitochondrial redox balance, enhancing caspase-dependent apoptosis. In an orthotopic mouse model of ovarian cancer, oral administration of PTC-028 as a single agent demonstrated significant antitumor activity comparable to standard cisplatin/paclitaxel therapy [188]. Researchers have also discovered another small molecule compound QW24, which can inhibit the expression of Bmi-1 through the lysosomal autophagy pathway, and can inhibit the growth of mouse xenograft tumors and liver metastasis, and prolong the survival period of mice [189]. Unfortunately, there have been no other reports of the anticancer effects of QW24, so its anti-cancer effect needs to be further verified. Table 3 summarizes the inhibitors of Bmi-1, the ways they regulate Bmi-1, and the regulatory mechanisms in tumors.
### Table 3. Inhibitors of Bmi-1.

| Inhibitor Name | Regulatory for Bmi-1 | Tumor Type | Regulatory Mechanism | References |
|----------------|----------------------|------------|----------------------|------------|
| PTC-209 Reduces transcript levels | Cervical cancer | Promotes cell cycle arrest and apoptosis | [179] |
| PTC-209 Reduces transcript levels | Colon cancer | Developed an orally active, easily synthesized | [180] |
| PTC-209 Reduces transcript levels | Alveolar rhabdomyosarcoma | Activates the Hippo pathway | [181] |
| PTC-209 Reduces transcript levels | Glioblastoma | Inhibits glioblastoma cell proliferation and migration | [182] |
| PTC-209 Reduces transcript levels | Ovarian cancer | Inhibits autophagy through ATP depletion | [183] |
| PTC-209 Reduces transcript levels | Lung cancer cells, breast cancer cells and colon cancer cells | Promotes cell G0/G1 arrest and apoptosis | [184] |
| PTC-209 Reduces transcript levels | PTC596 | Reduces protein levels of BMI-1 | [185] |
| PTC-209 Reduces transcript levels | Myeloma | Myeloma | [186] |
| PTC-209 Reduces transcript levels | AML | AML | [187] |
| PTC-209 Reduces transcript levels | Glioblastoma | Glioblastoma | [188] |
| PTC-209 Reduces transcript levels | Acute myeloid leukemia | Acute myeloid leukemia | [189] |
| PTC-209 Reduces transcript levels | Acute Leukemia Cells | Acute Leukemia Cells | [190] |
| PTC-209 Reduces transcript levels | Breast cancer | Breast cancer | [191] |
| PTC-209 Reduces transcript levels | Biliary tract cells | Biliary tract cells | [192] |
| PTC-209 Reduces transcript levels | Chronic myeloid leukemia cells | Chronic myeloid leukemia cells | [193] |
| PTC-209 Reduces transcript levels | MM | MM | [194] |
| PTC-209 Reduces transcript levels | HNSCC | HNSCC | [195] |
| RU-A1 Bind to the Bmi-1 mRNA | Hepatocellular carcinoma | Hepatocellular carcinoma | [196] |
| RU-A1 Bind to the Bmi-1 mRNA | Posttranslational modification | Multiple myeloma | [197] |
| RU-A1 Bind to the Bmi-1 mRNA | Hyperphosphorylation | Ovarian cancer | [198] |
| RU-A1 Bind to the Bmi-1 mRNA | PTC-028 | PTC-028 | [199] |
| RU-A1 Bind to the Bmi-1 mRNA | Alveolar rhabdomyosarcoma | Alveolar rhabdomyosarcoma | [200] |
| RU-A1 Bind to the Bmi-1 mRNA | Diffuse intrinsic pontine glioma (DIPG) | Diffuse intrinsic pontine glioma (DIPG) | [201] |
| SH498 | SH498 | SH498 | [202] |
| Artemisinin Protein and transcript levels | Artemisinin Protein and transcript levels | Artemisinin Protein and transcript levels | [203] |
| PRT4165 Down-regulating Bmi-1/RING1A self-ubiquitination | PRT4165 Down-regulating Bmi-1/RING1A self-ubiquitination | PRT4165 Down-regulating Bmi-1/RING1A self-ubiquitination | [204] |
| CDDO-Me ESCC | CDDO-Me ESCC | CDDO-Me ESCC | [205] |
6. Future Research and Conclusions

PcG family member Bmi-1 plays a vital role in the proliferation, apoptosis, metastasis, and chemical sensitivity of cancer cells. The discovery of the biogenesis and function of non-coding RNA has improved our understanding of the complexity of the human genome. With the deepening of research, it has been found that non-coding RNA is involved in the regulation of the cell cycle, proliferation, and differentiation, especially in the occurrence and development of cancer. Many miRNAs inhibit Bmi-1 expression by targeting the 3′UTR [22]. That means that these miRNAs can also affect cancer proliferation, migration, invasion, apoptosis, and drug sensitivity [22]. Thus, the interaction between miRNA and Bmi-1 plays an important role in the occurrence and development of cancer. This also provides new strategies for cancer treatment. However, at present, the research on the interaction between miRNA and Bmi-1 remains in the initial stages, and there are many problems still to be solved.

As a proto-oncogene, Bmi-1 has been confirmed to be highly expressed in a variety of tumors. It is related to the clinical stage, pathological classification, and lymph node metastasis, and can be used as one of the predictors for prognosis and recurrence in tumor patients. With the development of molecular biological technology and the application of gene chip technology, development is expected of a microfluidic multi-indicator joint inspection chip, a circulating cancer-cell capture chip, and other devices for automatic detection of Bmi-1 expression [208–210]. In addition, Bmi-1 is involved in the occurrence and development of many tumors, and the targeted therapy of cancer stem cells is an important measure for future development. However, there is currently no drug that can be used clinically to target Bmi-1 specifically. Therefore, the discovery of new small-molecule compounds that specifically inhibit Bmi-1 will be the focus of future research.

Author Contributions: L.Y. and H.C. contributed to the conception and design of the study. J.X. collected the related papers and was a major contributor in writing the manuscript. L.L. generated the table and prepared the figures. P.S. revised the article. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Fundamental Research Funds for the Central Universities (XDJK2020B006).

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| 4EBP1 | Eukaryotic Translation Initiation Factor 4E Binding Protein 1 |
| AKT | Protein kinase B |
| AML | Acute myeloid leukemia |
| AMPK | AMP-activated protein kinase |
| ATP | Adenosine triphosphate |
| BCSCs | Breast cancer stem cells |
| Bmi-1 | B Lymphoma Mo-MLV Insertion Region 1 Homolog |
| CBX4 | Chromobox 4 |
| Chk2 | Checkpoint Kinase 2 |
| c-MYC | Myc proto-oncogene protein |
| CSCs | Cancer stem cells |
| DDR | DNA damage response |
| DKK1 | Dickkopf WNT Signaling Pathway Inhibitor 1 |
| DUB3 | Deubiquitinating Protein 3 |
| Acronym | Definition |
|---------|------------|
| E2F1 | E2F Transcription Factor 1 |
| EMT | Epithelial-mesenchymal-like transformation |
| FoxM1 | Forkhead Box M1 |
| H2AX | H2A.X Variant Histone |
| HDACs | Histone Deacetylase |
| HoxC13 | Homeobox C13 |
| HSCs | Hematopoietic stem cells |
| hTERT | Human telomerase reverse transcriptase |
| HTH structure | Helix-turn-helix structure |
| IR | Ionizing radiation |
| KLF4 | Kruppel-like Factor 4 |
| Mcl-1 | Myeloid cell leukemia sequence 1 |
| MD-2 | Myeloid Differentiation Protein-2 |
| MDM2 | E3 ubiquitin-protein ligase Mdm2 |
| MeI18 | Polycomb Group RING Finger 2 |
| miRNAs | MicroRNAs |
| MM | Multiple myeloma |
| MM-MΦs | Myeloma-associated macrophages |
| MMP2 | Matrix Metalloproteinase2 |
| MMP9 | Matrix Metalloproteinase 9 |
| mTOR | mammalian target of rapamycin |
| MYC-N | MYCN Proto-Oncogene, BHLH Transcription Factor |
| MyD88 | MYD88 Innate Immune Signal Transduction Adaptor |
| Nanog | Homeobox protein NANOG |
| ncRNAs | Non-coding RNA |
| NF-κB | Nuclear factor kappa-B |
| NLRP3 | NACHT, LRR and PYD domains-containing protein 3 |
| NLRP3 | NOD-like receptors (NLRs) family member |
| NLS | Nuclear localization signal |
| Noxa | Phorbol-12-Myristate-13-Acetate-Induced Protein 1 |
| NSCs | Neural stem cells |
| NSPC | Neural stem cells and progenitor cells |
| P21 | Cyclin-dependent kinase inhibitor 1A |
| P53 | Tumor Protein P53 |
| PcG | Polycomb group |
| PRC1 | polycomb repressive complex1 |
| PRC2 | polycomb repressive complex 2 |
| PRO51 | Protein S |
| PTEN | Phosphatidylinositol3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN |
| PTMs | Post-translational modifications |
| RKIP | Raf kinase inhibitory protein |
| ROS | Proto-oncogene tyrosine-protein kinase ROS |
| SALL4 | Spalt Like Transcription Factor 4 |
| Slug | Snail Family Transcriptional Repressor 2 |
| Snail | Zinc finger protein SNAI1 |
| SP1 | Transcription factor Sp1 |
| Stat3 | Signal transducer and activator of transcription 3 |
| TAMs | Tumor-associated macrophages |
| TLR4 | Toll-like receptor 4 |
| TME | Tumor microenvironment |
| Twist1 | Twist Family BHLH Transcription Factor 1 |
| USP22 | Ubiquitin Specific Peptidase 22 |
| VEGF | Vascular Endothelial Growth Factor A |
| VEGF-C | Vascular Endothelial Growth Factor C |
| WWOX | WW Domain Containing Oxidoreductase |
| ZEB1 | Zinc Finger E-Box Binding Homeobox 1 |
References

1. Wang, W.; Qin, J.J.; Voruganti, S.; Nag, S.; Zhou, J.; Zhang, R. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med. Res. Rev. 2015, 35, 1220–1267. [CrossRef] [PubMed]

2. Kanno, R.; Janakiramam, H.; Kanno, M. Epigenetic regulator polycomb group protein complexes control cell fate and cancer. Cancer Sci. 2008, 99, 1077–1084. [CrossRef] [PubMed]

3. Schwartz, Y.B.; Pierrotta, V. Polycomb complexes and epigenetic states. Curr. Opin. Cell Biol. 2008, 20, 266–273. [CrossRef] [PubMed]

4. Liu, S.L.; Dontu, G.; Mantle, I.D.; Patel, S.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66, 6063–6071. [CrossRef]

5. Park, I.K.; Qian, D.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S.; Morrison, S.J.; Clarke, M.F. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003, 423, 302–305. [CrossRef] [PubMed]

6. Jiang, L.; Li, J.; Song, L. Bmi-1, stem cells and cancer. Acta Biochim. Biophys. Sin. 2009, 41, 527–534. [CrossRef]

7. Gomes, A.Q.; Nolasco, S.; Soares, H. Non-coding RNAs: Multi-tasking molecules in the cell. Int. J. Mol. Sci. 2013, 14, 16101–16139. [CrossRef]

8. Wei, J.W.; Huang, K.; Yang, C.; Kang, C.S. Non-coding RNAs as regulators in epigenetics. Oncol. Rep. 2017, 37, 3–9. [CrossRef] [PubMed]

9. Xu, Z.J.; Yan, Y.L.; Qian, L.; Gong, Z.C. Long non-coding RNAs act as regulators of cell autophagy in diseases (Review). Oncol. Rep. 2017, 37, 1359–1366. [CrossRef] [PubMed]

10. Beermann, J.; Piccoli, M.T.; Vierreck, J.; Thum, T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol. Rev. 2016, 96, 1297–1325. [CrossRef] [PubMed]

11. de Almeida, R.A.; Fraczek, M.G.; Parker, S.; Delneri, D.; O’Keefe, R.T. Non-coding RNAs and disease: The classical ncRNAs make a comeback. Biochem. Soc. Trans. 2016, 44, 1073–1078. [CrossRef] [PubMed]

12. Wang, X.; Wang, C.; Zhang, X.; Hua, R.; Gan, L.; Huang, M.; Zhao, L.; Ni, S.; Guo, W. Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs. J. Hematol. Oncol. 2016, 9, 90. [CrossRef] [PubMed]

13. Wang, F.; Wu, H.; Fan, M.; Yu, R.; Zhang, Y.; Liu, J.; Zhou, X.; Cai, Y.; Huang, S.; Hu, Z.; et al. Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells. FASEB J. 2020, 34, 4266–4282. [CrossRef]

14. Alkema, M.J.; Wiegant, J.; Raap, A.K.; Berns, A.; Vanlohuizen, M. Characterization And Chromosomal Localization Of The Human Protooncogene Bmi-1. Hum. Mol. Genet. 1993, 2, 1597–1603. [PubMed]

15. Sahasrabuddhe, A.A. BMI1: A Biomarker of Hematologic Malignancies. Biomark. Cancer 2016, 8, 65–75. [CrossRef] [PubMed]

16. Voncken, J.W.; Schweizer, D.; Aagaard, L.; Sattler, L.; Jantsch, M.F.; van Loenhuis, M. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J. Cell Sci. 1999, 112 Pt 24, 4627–4639. [CrossRef] [PubMed]

17. Liu, Y.; Liu, F.; Yu, H.; Zhao, X.; Sashida, G.; Deblasio, A.; Harr, M.; She, Q.B.; Chen, Z.; Lin, H.K.; et al. Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci. Signal. 2012, 5, ra77. [CrossRef] [PubMed]

18. Karvonen, H.; Barker, H.; Kaleva, L.; Niininen, W.; Ungureanu, D. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Cells 2019, 8, 812. [CrossRef] [PubMed]

19. Voncken, J.W.; Niessen, H.; Neufeld, B.; Rennefahrt, U.; Dahlmans, V.; Kubben, N.; Holzer, B.; Ludwig, S.; Rapp, U.R. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein BMI1. J. Biol. Chem. 2005, 280, 5178–5187. [CrossRef]

20. Ismail, I.H.; Gagné, J.P.; Caron, M.C.; McDonald, D.; Xu, Z.; Masson, J.Y.; Poirier, G.G.; Hendzel, M.J. CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. Nucleic Acids Res. 2012, 40, 5497–5510. [CrossRef]

21. Zhang, Z.; Oh, M.; Sasaki, J.I.; Nör, J.E. Inverse and reciprocal regulation of p53/p21 and Bmi-1 modulates vasculogenic differentiation of dental pulp stem cells. Cell Death Dis. 2021, 12, 644. [CrossRef] [PubMed]

22. Li, Y.; Wang, L.; Liu, J.; Zhang, P.; An, M.; Han, C.; Li, Y.; Guan, X.; Zhang, K. O-GlcNAcylation modulates Bmi-1 protein stability and potential oncogenic function in prostate cancer. Oncogene 2017, 36, 6293–6305. [CrossRef] [PubMed]

23. You, D.; Wang, D.; Liu, P.; Chu, Y.; Zhang, X.; Ding, X.; Li, X.; Mao, T.; Jing, X.; Tian, Z.; et al. MicroRNA-498 inhibits the proliferation, migration and invasion of gastric cancer through targeting BMI-1 and suppressing AKT pathway. Hum. Cell 2020, 33, 366–376. [CrossRef]

24. Yu, W.W.; Jiang, H.; Zhang, C.T.; Peng, Y. The SNAIL/miR-128 axis regulated growth, invasion, metastasis, and epithelial-to-mesenchymal transition of gastric cancer. Oncotarget 2017, 8, 39280–39295. [CrossRef]

25. Wu, C.; Zheng, X.; Li, X.; Fesler, A.; Hu, W.; Chen, L.; Xu, B.; Wang, Q.; Tong, A.; Burke, S.; et al. Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation. Oncotarget 2016, 7, 14522–14536. [CrossRef]

26. Xu, L.; Li, Y.; Yan, D.; He, J.; Liu, D. MicroRNA-183 inhibits gastric cancer proliferation and invasion via directly targeting Bmi-1. Oncol. Lett. 2014, 8, 2345–2351. [CrossRef]

27. Wu, Y.; Tian, S.; Chen, Y.; Ji, M.; Qu, Y.; Hou, P. miR-218 inhibits gastric tumorigenesis through regulating Bmi-1/Akt signaling pathway. Pathol. Res. Pract. 2019, 215, 243–250. [CrossRef]
28. Chai, Y.; Du, Y.; Zhang, S.; Xiao, J.; Luo, Z.; He, F.; Huang, K. MicroRNA-485-5p reduces O-GlcNAcylation of Bmi-1 and inhibits colorectal cancer proliferation. *Exp. Cell Res.* 2018, 368, 111–118. [CrossRef] [PubMed]

29. He, X.; Dong, Y.; Wu, C.W.; Zhao, Z.; Ng, S.S.; Chan, F.K.; Sung, J.J.; Yu, J. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. *Med. Mol. 2013, 18, 1491–1498. [CrossRef]

30. Xu, Z.; Tao, J.; Chen, P.; Chen, L.; Sharma, S.; Wang, G.; Dong, Q. Sodium Butyrate Inhibits Colorectal Cancer Cell Migration by Downregulating Bmi-1 Through Enhanced miR-200c Expression. *Med. Nutr. Food Res.* 2018, 62, e1700844. [CrossRef]

31. Zhou, L.; Zhang, W.G.; Wang, D.S.; Tao, K.S.; Song, W.J.; Dou, K.F. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1. *Oncol. Rep.* 2014, 32, 1734–1740. [CrossRef] [PubMed]

32. Guo, S.; Xu, X.; Tang, Y.; Zhang, C.; Li, J.; Ouyang, Y.; Ju, J.; Bie, P.; Wang, H. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. *Cancer. Lett.* 2014, 344, 40–46. [CrossRef] [PubMed]

33. Yu, X.; Jiang, X.; Li, H.; Guo, L.; Jiang, W.; Lu, S.H. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. *Stem Cells Dev.* 2014, 23, 576–585. [CrossRef]

34. Kim, J.S.; Choi, D.W.; Kim, C.S.; Yu, S.K.; Kim, H.J.; Go, D.S.; Lee, S.A.; Moon, S.M.; Kim, S.G.; Chun, H.S.; et al. MicroRNA-203 Induces Apoptosis by Targeting Bmi-1 in YD-38 Ovarian Cancer Cells. *Anticancer Res.* 2018, 38, 3477–3485. [CrossRef]

35. Wu, J.; Jiang, Z.M.; Xie, Y.; He, X.Q.; Lin, X.H.; Hu, J.L.; Peng, Y.Z. miR-218 suppresses the growth of hepatocellular carcinoma by inhibiting the expression of proto-oncogene Bmi-1. *J. BIOL 2018, 23, 604–610.

36. Yang, F.; Lv, L.Z.; Cai, Q.C.; Jiang, Y. Potential roles of EZH2, Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma cell line Hep3B. *World J. Gastroenterol.* 2015, 21, 13268–13276. [CrossRef]

37. Shao, Y.; Zhang, D.; Li, X.; Yang, J.; Chen, L.; Ning, Z.; Xu, Y.; Deng, G.; Tao, M.; Zhu, Y.; et al. MicroRNA-203 Increases Cell Radiosensitivity via Directly Targeting Bmi-1 in Hepatocellular Carcinoma. *Med. Pharm. 2018, 15, 3205–3215. [CrossRef] [PubMed]

38. Fu, W.M.; Tang, L.P.; Zhu, X.; Lu, Y.F.; Zhang, Y.L.; Lee, W.Y.; Wang, H.; Yu, Y.; Liang, W.C.; Ko, C.H.; et al. MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells. *Apoptosis 2015, 20, 75–82. [CrossRef] [PubMed]

39. Tu, K.; Li, C.; Zheng, X.; Yang, W.; Yao, Y.; Liu, Q. Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth. *Oncol. Rep.* 2014, 31, 1571–1577. [CrossRef]

40. Qi, X.; Li, J.; Zhou, C.; Lv, C.; Tian, M. MicroRNA-320a inhibits cell proliferation, migration and invasion by targeting BMI-1 in nasopharyngeal carcinoma. *FEBS Lett.* 2014, 588, 3732–3738. [CrossRef] [PubMed]

41. Liu, G.F.; Zhang, S.H.; Li, X.F.; Cao, L.Y.; Fu, Z.Z.; Yu, S.N. Overexpression of microRNA-132 enhances the radiosensitivity of cervical cancer cells by down-regulating Bmi-1 in Hepatocellular Carcinoma. *Med. Pharm. 2015, 21, 13268–13276. [CrossRef] [PubMed]

42. Rong, X.; Gao, W.; Yang, X.; Guo. J. Downregulation of hsa_circ_0007534 restricts the proliferation and invasion of cervical cancer through regulating miR-498/BMI-1 signaling. *Life Sci. 2019, 235, 116785. [CrossRef]

43. Li, Q.; Wang, W.; Zhang, M.; Sun, W.; Shi, W.; Li, F. Circular RNA circ-0016068 Promotes the Growth, Migration, and Invasion of Prostate Cancer Cells by Regulating the miR-330-3p/BMI-1 Axis as a Competing Endogenous RNA. *Front. Cell Dev. Biol. 2020, 8, 827. [CrossRef] [PubMed]

44. Tang, Y.; Liu, J.; Li, X.; Wang, W. Exosomal circRNA HIPK3 knockdown inhibited cell proliferation and metastasis in prostate cancer by regulating miR-212/218-1 pathway. *J. Biosci. 2021, 46, 69. [CrossRef]

45. Khan, A.P.; Poisson, L.M.; Bhat, V.B.; Fermin, D.; Zhao, R.; Kalyana-Sundaram, S.; Michailidis, G.; Nesvizhskii, A.I.; Omenn, G.S.; Chinnaiyan, A.M.; et al. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. *Mol. Cell. Proteom.* 2010, 9, 298–312. [CrossRef]

46. Jin, M.; Zhang, T.; Liu, C.; Badeaux, M.A.; Liu, B.; Liu, R.; Jeter, C.; Chen, X.; Vlassov, A.V.; Tang, D.G. MiR-128 increases cell radiosensitivity by inhibiting the expression of proto-oncogene Bmi-1 in Hepatocellular Carcinoma. *Cancer Res. 2014, 74, 4183–4195. [CrossRef] [PubMed]

47. Feng, B.; Wang, R.; Chen, L.B. Review of miR-200b and cancer chemosensitivity. *Biomed. Pharm.* 2012, 66, 397–402. [CrossRef] [PubMed]

48. Yu, J.; Lu, Y.; Cui, D.; Li, E.; Zhu, Y.; Zhao, Y.; Hao, F.; Xia, S. miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1. *Oncol. Rep.* 2014, 31, 910–918. [CrossRef] [PubMed]

49. Xuan, H.; Xue, W.; Pan, J.; Sha, J.; Dong, B.; Huang, Y. Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting BMI-1. *Biochemistry 2015, 80, 276–283. [CrossRef]

50. Kim, J.S.; Choi, D.W.; Kim, C.S.; Yu, S.K.; Kim, H.J.; Go, D.S.; Lee, S.A.; Moon, S.M.; Kim, S.G.; Chun, H.S.; et al. MicroRNA-203 Induces Apoptosis by Targeting Bmi-1 in YD-38 Ovarian Cancer Cells. *Anticancer Res.* 2018, 38, 3477–3485. [CrossRef]

51. Li, F.; Liang, A.; Lv, Y.; Liu, G.; Jiang, A.; Liu, P. MicroRNA-200c Inhibits Epithelial-Mesenchymal Transition by Targeting the BMI-1 Gene Through the Phospho-AKT Pathway in Endometrial Carcinoma Cells In Vitro. *Med. Sci. Monit.* 2017, 23, 5139–5149. [CrossRef] [PubMed]

52. Dong, P.; Kaneuchi, M.; Watari, H.; Hamada, J.; Sudo, S.; Ju, J.; Sakuragi, N. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. *Mol. Cancer 2011, 10, 99. [CrossRef]

53. Wang, L.; Liu, J.L.; Yu, L.; Liu, X.X.; Wu, H.M.; Lei, F.Y.; Wu, S.; Wang, X. Downregulated miR-495 [Corrected] Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer. *Medicine 2015, 94, e718. [CrossRef]
54. Zhu, Y.; Yu, F.; Jiao, Y.; Feng, J.; Tang, W.; Yao, H.; Gong, C.; Chen, J.; Su, F.; Zhang, Y.; et al. Reduced miR-28 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCG5. *Clin. Cancer Res.* **2011**, *17*, 7105–7115. [CrossRef]

55. Bhattacharya, R.; Nicoloso, M.; Arvizo, R.; Wang, E.; Cortez, A.; Rossi, S.; Calin, G.A.; Mukherjee, P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. *Cancer Res.* **2009**, *69*, 9090–9095. [CrossRef] [PubMed]

56. Zhang, X.L.; Sun, B.L.; Tian, S.X.; Li, L.; Zhang, Y.C.; Shi, P.P. MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, *23*, 3635–3644. [CrossRef]

57. Li, B.; Chen, H.; Wu, N.; Zhang, W.J.; Shang, L.X. Derepression of miR-128 in ovarian cancer promotes cisplatin resistance. *Int. J. Gynecol. Cancer* **2014**, *24*, 1381–1388. [CrossRef]

58. Godlewski, J.; Nowicki, M.O.; Bronisz, A.; Williams, S.; Otsuki, A.; Nuovo, G.; Raychaudhury, A.; Newton, H.B.; Chiocca, E.A.; Lawler, S. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. *Cancer Res.* **2008**, *68*, 9125–9130. [CrossRef] [PubMed]

59. Zhang, X.; Wei, C.; Li, J.; Liu, J.; Qu, J. MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1. *Oncol. Rep.* **2017**, *37*, 1849–1856. [CrossRef]

60. Tu, Y.; Gao, X.; Li, G.; Fu, H.; Cui, D.; Liu, H.; Jin, W.; Zhang, Y. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. *Cancer Res.* **2013**, *73*, 6046–6055. [CrossRef]

61. Cui, J.G.; Zhao, Y.; Sethi, P.; Li, Y.Y.; Mahta, A.; Culicchia, F.; Luktiw, W.J. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARPS (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. *J. Neurooncol.* **2010**, *98*, 297–304. [CrossRef] [PubMed]

62. Ye, L.; Yu, G.; Wang, C.; Du, B.; Sun, D.; Liu, J.; Qi, T.; Yu, X.; Wei, W.; Cheng, J.; et al. MicroRNA-128a, BMI1 polycomb ring finger oncogene, and reactive oxygen species inhibit the growth of U-87 MG glioblastoma cells following exposure to X-ray radiation. *Mol. Med. Rep.* **2015**, *12*, 6247–6254. [CrossRef] [PubMed]

63. Chen, F.; Chen, L.; He, H.; Huang, W.; Zhang, R.; Li, P.; Meng, Y.; Jiang, X. Up-regulation of microRNA-16 in Glioblastoma Inhibits βcatenin mediated cell migration and invasion by targeting BMI-1 and Twist1. *Cancer Res.* **2017**, *78*, 4185–4195. [CrossRef] [PubMed]

64. Peng, H.; Liang, D.; Li, B.; Liang, C.; Huang, W.; Lin, H. MicroRNA-320a protects against osteoarthritis cartilage degeneration by regulating the expressions of BMI-1 and RUNX2 in chondrocytes. *Pharmazie* **2017**, *72*, 223–226. [CrossRef]

65. Lai, G.H.; Huang, A.L.; Zhao, Z.; Lu, X.H.; Zu, W.X. MicroRNA-218 promotes osteosarcoma cell apoptosis by down-regulating BMI1. *Oncol. Rep.* **2017**, *37*, 1849–1856. [CrossRef] [PubMed]

66. Liu, S.; Tetzlaff, M.T.; Cui, R.; Xu, X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. *Am. J. Pathol.* **2012**, *181*, 1823–1835. [CrossRef] [PubMed]

67. Bassiouni, M.; Dos Santos, A.; Avci, H.X.; Löwenheim, H.; Müller, M. Bmi1 Loss in the Organ of Corti Results in p16ink4a Upregulation and Reduced Cell Progenitors of Otic Progenitors In Vitro. *PLoS ONE* **2016**, *11*, e0164579. [CrossRef]

68. Cao, R.; Tsukada, Y.; Zhang, Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. *Mol. Cell* **2005**, *20*, 845–854. [CrossRef]

69. Gao, F.; Huang, W.; Zhang, Y.; Tang, S.; Zheng, L.; Ma, F.; Wang, Y.; Tang, H.; Li, X. Hes1 promotes cell proliferation and migration by activating Bmi-1 and PTEN/Akt/GSK3β pathway in human colon cancer. *Oncotarget* **2015**, *6*, 38667–38680. [CrossRef]
79. Dimri, G.P.; Martinez, J.L.; Jacobs, J.J.; Kebulsey, P.; Itahana, K.; Van Lohuizen, M.; Campisi, J.; Wazer, D.E.; Band, V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002, 62, 4736–4745.

80. Yamashita, M.; Kuwahara, M.; Suzuki, A.; Hirahara, K.; Shinmoku, R.; Hosokawa, H.; Hasegawa, A.; Motohashi, S.; Iwama, A.; Nakayama, T. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J. Exp. Med. 2008, 205, 1109–1120. [CrossRef]

81. Park, I.K.; Morrison, S.J.; Clarke, M.F. Bmi1, stem cells, and senescence regulation. J. Clin. Investig. 2004; 113, 175–179. [CrossRef] [PubMed]

82. Ren, H.; Du, P.; Ge, Z.; Jin, Y.; Ding, D.; Liu, X.; Zou, Q. TWIST1 and BMI1 in Cancer Metastasis and Chemoresistance. J. Cell Mol. Med. 2019; 23, 7949–7958. [CrossRef] [PubMed]

83. Yu, F.; Zhou, C.; Zeng, H.; Liu, Y.; Li, S. BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Mol. Cell Biol. 2011, 31, 689–696. [CrossRef] [PubMed]

84. Siddique, H.R.; Saleem, M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells 2012, 30, 372–378. [CrossRef]

85. Hu, C.; Zhang, Q.; Tang, Q.; Zhou, H.; Liu, W.; Wang, Q.; Zhang, J.; Zhou, M.; et al. CBX4 promotes the proliferation and metastasis of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels. Nucleic Acid Ther. 2014, 24, 210–216. [CrossRef]

86. Ginjala, V.; Nacerddine, K.; Kulkarni, A.; Oza, J.; Hill, S.J.; Yao, M.; Citterio, E.; van Lohuizen, M.; Ganesan, S. BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Mol. Cell Biol. 2017, 37, 2382–2390. [CrossRef]

87. Ma, D.Q.; Zhang, Y.H.; Ding, D.P.; Li, J.; Chen, L.L.; Tian, Y.Y.; Ao, K.J. Effect of Bmi-1-mediated NF-kB signaling pathway on the stem-like properties of CD133+ human liver cancer cells. Cancer Biomark. 2018, 22, 575–585. [CrossRef]

88. Zheng, X.; Wang, Y.; Liu, B.; Liu, C.; Liu, D.; Zhu, J.; Yang, C.; Yan, J.; Liao, X.; Meng, X.; et al. Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels. Nucleic Acid Ther. 2014, 24, 210–216. [CrossRef]

89. Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 2017, 17, 528–542. [CrossRef]

90. Dey, A.; Mustafi, S.B.; Saha, S.; Kumar Dhar Dwivedi, S.; Bhattacharya, R. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy 2016, 12, 659–670. [CrossRef] [PubMed]

91. Chen, F.; Li, Y.; Wang, L.; Hu, L. Knockdown of BMI-1 causes cell-cycle arrest and derepresses p16INK4a, HOXA9 and HOXC13 mediated necroptosis. Chin. J. Cancer Res. 2010, 22, 10107. [CrossRef] [PubMed]

92. Boros, L.; Salloum, G.; Czarnitzki, U.; Hettich, R.; Driessen, J.M.; Haussler, S. BMI1 promotes the proliferation and inhibits autophagy of breast cancer cells by activating COPZ1. Clin. Transl. Oncol. 2022; Online ahead of print. [CrossRef]

93. Griffith, J.; Andrade, D.; Mehta, M.; Berry, W.; Benbrook, D.M.; Aravindan, N.; Herman, T.S.; Ramesh, R.; Munshi, A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol. Rep. 2017, 37, 2382–2390. [CrossRef] [PubMed]

94. Kameyama, A.; Nishijima, R.; Yamakoshi, K. Bmi-1 regulates mucin levels and mucin O-glycosylation in the submandibular gland of mice. PloS ONE 2021, 16, e0245607. [CrossRef]

95. Liu, Y.L.; Jiang, S.X.; Yang, Y.M.; Xu, H.; Liu, J.L.; Wang, X.S. USP22 acts as an oncogene by the activation of BMI-1-mediated Mcl-1 Stabilization. Cancer Sci. 2021, 102, 983–990. [CrossRef]

96. Griffith, J.; Andrade, D.; Mehta, M.; Berry, W.; Benbrook, D.M.; Aravindan, N.; Herman, T.S.; Ramesh, R.; Munshi, A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol. Rep. 2017, 37, 2382–2390. [CrossRef] [PubMed]

97. Wu, K.; Woo, S.M.; Seo, S.U.; Kwon, T.K. Inhibition of BMI1 Induces Apoptosis through Downregulation of DUB3-Mediated Mcl-1 Stabilization. Int. J. Mol. Sci. 2020, 21, 10107. [CrossRef] [PubMed]

98. Kameyama, A.; Nishijima, R.; Yamakoshi, K. Bmi-1 regulates mucin levels and mucin O-glycosylation in the submandibular gland of mice. PloS ONE 2021, 16, e0245607. [CrossRef]

99. Li, J.; Gong, L.Y.; Song, L.B.; Jiang, L.L.; Liu, L.P.; Wu, J.; Yuan, J.; Cai, J.C.; He, M.; Wang, L.; et al. Oncoprotein Bmi-1 renders human gallbladder carcinoma proliferation. Oncol. Lett. 2019, 18, 1365–1371. [CrossRef]

100. Levy, J.M.M.; Towers, C.G.; Thorburn, A. Targeting autophagy in cancer. Nat. Rev. Cancer 2017, 17, 528–542. [CrossRef]

101. Dey, A.; Mustafi, S.B.; Saha, S.; Kumar Dhar Dwivedi, S.; Bhattacharya, R. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy 2016, 12, 659–670. [CrossRef] [PubMed]

102. Chen, S.; Li, H.; Chen, S.; Wang, B.; Zhang, K. BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway. Am. J. Physiol. Heart Circ. Physiol. 2019, 316, H61–H69. [CrossRef]
105. Mourgues, L.; Imbert, V.; Nebout, M.; Colosetti, P.; Neffati, Z.; Lagadec, P.; Verhoeven, E.; Peng, C.; Duprez, E.; Legros, L.; et al. The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. *Leukemia* 2015, 29, 1993–2002. [CrossRef]

106. Yu, J.; Chen, L.; Bao, Z.; Liu, Y.; Liu, G.; Li, F.; Li, L. BMI-1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor. *Oncol. Rep.* 2020, 43, 1630–1640. [CrossRef] [PubMed]

107. Li, Y.; Tian, Z.; Tan, Y.; Lian, G.; Chen, S.; Chen, S.; Li, J.; Li, X.; Huang, K.; Chen, Y. Bmi-1-induced miR-27a and miR-155 promote tumor metastasis and chemoresistance by targeting RKIP in gastric cancer. *Mol. Cancer* 2020, 19, 109. [CrossRef] [PubMed]

108. Zhang, X.; Tian, T.; Sun, W.; Liu, C.; Fang, X. Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. *Medicine* 2017, 96, e7346. [CrossRef]

109. Pourjafar, M.; Samadi, P.; Karami, M.; Najafi, R. Assessment of clinicopathological and prognostic relevance of BMI-1 in patients with colorectal cancer: A meta-analysis. *Biotechnol. Appl. Biochem.* 2021, 68, 1313–1322. [CrossRef]

110. Li, X.; Yang, Z.; Song, W.; Zhou, L.; Li, Q.; Tao, K.; Zhou, J.; Wang, X.; Zheng, Z.; You, N.; et al. Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)-2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. *Int. J. Oncol.* 2013, 43, 793–802. [CrossRef]

111. Jiang, L.; Wu, J.; Yang, Y.; Liu, L.; Song, L.; Li, J.; Li, M. Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway. *BMC Cancer* 2012, 12, 406. [CrossRef]

112. Ye, K.; Chen, Q.W.; Sun, Y.F.; Lin, J.A.; Xu, J.H. Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-kB signaling. *J. Cell Biochem.* 2018, 119, 1922–1930. [CrossRef] [PubMed]

113. Chagraoui, J.; Hébert, J.; Girard, S.; Sauvageau, G. An anticlastogenic function for the Polycomb Group gene Bmi1. *Proc. Natl. Acad. Sci. USA* 2011, 108, 5284–5289. [CrossRef] [PubMed]

114. Gieni, R.S.; Ismail, I.H.; Campbell, S.; Hendzel, M.J. Polycomb group proteins in the DNA damage response: A link between radiation resistance and “stemness”. *Cell Cycle* 2011, 10, 883–894. [CrossRef] [PubMed]

115. Liu, J.; Cao, L.; Chen, J.; Song, S.; Lee, I.H.; Quijano, C.; Liu, H.; Keyvanfar, K.; Chen, H.; Cao, L.Y.; et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. *Nature* 2009, 459, 387–392. [CrossRef]

116. Dong, Q.; Oh, J.E.; Chen, W.; Kim, R.H.; Shin, K.H.; McBride, W.H.; Park, N.H.; Kang, M.K. Radioprotective effects of Bmi-1 in mouse thymus: Mice with Bmi-1 deficiency show increased radiosensitivity. *BMC Biotechnol.* 2021, 21, 126–130. [CrossRef]

117. Qin, Z.Y.; Gu, X.; Chen, Y.L.; Liu, J.B.; Hou, C.X.; Lin, S.Y.; Hao, N.N.; Liang, Y.; Chen, W.; Meng, H.Y. Toll-like receptor 4 activates the NF-κB/VEGF story: Another hint for proteasome involvement in glioma angiogenesis. *J. Investig. Dermatol.* 2011, 131, 1216–1225. [CrossRef]

118. Lin, X.; Ojo, D.; Wei, F.; Wong, N.; Gu, Y.; Tang, D. A Novel Aspect of Tumorigenesis-BMI1 Functions in Regulating DNA Damage Response. *Biomolecules* 2015, 5, 3396–3415. [CrossRef] [PubMed]

119. Ismail, I.H.; Andrin, C.; McDonald, D.; Hendzel, M.J. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. *J. Cell Biol.* 2010, 191, 45–60. [CrossRef]

120. Wang, E.; Bhattacharyya, S.; Szabolcs, A.; Rodriguez-Aguayo, C.; Jennings, N.B.; Lopez-Berestein, G.; Mukherjee, P.; Sood, A.K.; Bhattacharya, R. Enhancing chemotherapy response with BMI-1 silencing in ovarian cancer. *BMC Cancer* 2011, 11, e17918. [CrossRef] [PubMed]

121. Singh, N.; Baby, D.; Rajiguru, J.P.; Patil, P.B.; Thakkannavar, S.S.; Pujari, V.B. Inflammation and cancer. *Ann. Afr. Med.* 2019, 18, 121–126. [CrossRef]

122. Vlachostergios, P.J.; Papandreou, C.N. The Bmi-1/NF-kB/VEGF story: Another hint for proteasome involvement in glioma angiogenesis? *J. Cell Commun. Signal.* 2013, 7, 235–237. [CrossRef]

123. Sun, P.; Mu, Y.; Zhang, S. A novel NF-kB/MMP-3 signal pathway involves in the aggressiveness of glioma promoted by Bmi-1. *Tumour Biol.* 2014, 35, 12721–12727. [CrossRef]

124. Jiang, L.; Song, L.; Wu, J.; Yang, Y.; Zhu, X.; Hu, B.; Cheng, S.Y.; Li, M. Bmi-1 promotes glioma angiogenesis by activating NF-kB signaling. *PLoS ONE* 2013, 8, e55527. [CrossRef]

125. Qin, Z.Y.; Gu, X.; Chen, Y.L.; Liu, J.B.; Hou, C.X.; Lin, S.Y.; Hao, N.N.; Liang, Y.; Chen, W.; Meng, H.Y. Toll-like receptor 4 activates the NLRP3 inflammasome pathway and periodontal inflamming by inhibiting BMI1 expression. *Int. J. Mol. Med.* 2021, 47, 137–150. [CrossRef]

126. Spillane, J.B.; Henderson, M.A. Cancer stem cells: A review. *ANZ J. Surg.* 2007, 77, 464–468. [CrossRef]

127. Rafforst, E.M. Self-renewal of hematopoietic and leukemic stem cells: A central role for the Polycomb-group gene Bmi-1. *Trends Immunol.* 2003, 24, 522–524. [CrossRef]

128. Bruggeman, S.W.; Valk-Lingbeek, M.E.; van der Stoop, P.P.; Jacobs, J.J.; Kieboom, K.; Tanger, E.; Hulsman, D.; Leung, C.; Arsenijevic, Y.; Marino, S.; et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes Dev.* 2009, 13, 1489–1493. [CrossRef]

129. Zencak, D.; Lingbeek, M.; Kostic, C.; Tekaya, M.; Tanger, E.; Hornfeld, D.; Jaquet, M.; Munier, F.L.; Schorderet, D.F.; van Lohuizen, M.; et al. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. *J. Neurosci. Off. J. Soc. Neurosci.* 2005, 25, 5774–5783. [CrossRef]

130. Gargiulo, G.; Cesaroni, M.; Serresi, M.; de Vries, N.; Hulsman, D.; Bruggeman, S.W.; Lancini, C.; van Lohuizen, M. In Vivo RNAi Screen for BMI Targets Identifies TGF-beta/BMP-ER Stress Pathways as Key Regulators of Neural- and Malignant Glioma-Stem Cell Homeostasis. *Cancer Cell* 2013, 23, 660–676. [CrossRef]
130. Molófsky, A.V.; He, S.; Bydon, M.; Morrison, S.J.; Pardal, R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. *Genes Dev.* 2005, 19, 1432–1437. [CrossRef]

131. Zelentsova-Levitskaya, K.; Talmi, Z.; Abboud-Jarrous, G.; Capucha, T.; Sapir, T.; Burstyn-Cohen, T. Protein S Negatively Regulates Neural Stem Cell Self-Renewal through Bmi-1 Signaling. *Front. Mol. Neurosci.* 2017, 10, 124. [CrossRef]

132. Lessard, J.; Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukemic stem cells. *Nature* 2003, 423, 255–260. [CrossRef] [PubMed]

133. Cho, J.H.; Dimri, M.; Dimri, G.P. A Positive Feedback Loop Regulates the Expression of Polycomb Group Protein BMI1 via WNT Signaling Pathway. *J. Biol. Chem.* 2013, 288, 3406–3418. [CrossRef] [PubMed]

134. Lu, Y.W.; Li, J.; Guo, W.J. Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma. *Hum. Pathol.* 2012, 43, 2145–2150. [CrossRef]

135. Yan, K.S.; Chia, L.A.; Li, X.N.; Ootani, A.; Su, J.; Lee, J.Y.; Su, N.; Luo, Y.L.; Heilshorn, S.C.; Amieva, M.R.; et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. *Proc. Natl. Acad. Sci. USA* 2012, 109, 466–471. [CrossRef]

136. Zhang, Y.; Zhang, Y.L.; Chen, H.M.; Pu, H.W.; Ma, W.J.; Li, X.M.; Ma, H.; Chen, X. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma. *Cell Death Dis.* 2010, 7, 682–693. [CrossRef]

137. Bolomsky, A.; Schlangen, K.; Schreiner, W.; Zojer, N.; Ludwig, H. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. *Cell Stem Cell* 2010, 7, 568–579. [CrossRef]

138. Li, D.W.; Tang, H.M.; Fan, J.W.; Yan, D.W.; Zhou, C.Z.; Li, S.X.; Wang, X.L.; Peng, Z.H. Expression level of Bmi-1 oncoprotein is a new independent predictor of poor outcome in patients with ovarian carcinoma. *BMC Cancer* 2013, 13, 38–44. [CrossRef]

139. Liu, W.L.; Guo, X.Z.; Zhang, L.J.; Wang, J.Y.; Zhang, G.; Guan, S.; Chen, Y.M.; Kong, Q.L.; Xu, L.H.; Li, M.Z.; et al. Prognostic relevance of Bmi-1 expression in endometrial carcinoma and its precancerous lesion. *Int. J. Gynecol. Cancer* 2014, 24, 1597–1603. [PubMed]

140. Zhao, J.; Luo, X.D.; Da, C.L.; Xin, Y. Clinicopathological significance of B-cell-specific Moloney murine leukemia virus insertion site 1 expression in gastric cancer and its precancerous lesion. *World J. Gastroenterol.* 2009, 15, 2145–2150. [CrossRef]

141. Zhang, D.; Huang, J.; Wang, F.; Ding, H.; Cui, Y.; Yang, Y.; Xu, J.; Luo, H.; Gao, Y.; Pan, L.; et al. BMI1 regulates multiple myeloma-associated macrophage’s pro-myeloma functions. *Cell Death Dis.* 2021, 12, 495. [CrossRef]

142. Liu, J.; Liu, K.; Jiang, X.; Wang, X.; Chen, Y.; Cui, X.; Pang, L.; Li, S.; Liu, C.; Zou, H.; et al. Clinicopathological significance of Bmi-1 overexpression in esophageal cancer: A meta-analysis. *Biomark. Med.* 2018, 12, 71–81. [CrossRef]

143. Sugihara, H.; Ishimoto, T.; Watanabe, M.; Sawahayama, H.; Iwatsuki, M.; Baba, Y.; Komohara, Y.; Takeyama, M.; Baba, H. Identification of miR-30e regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer. *PloS ONE* 2013, 8, e61839. [CrossRef]

144. Song, Y.Q.; Liu, B.; Zheng, H.Y.; He, Y.J.; Gu, J.; Li, F.; Li, Y. Overexpression of BMI-1 is associated with poor prognosis in cervical cancer. *Asia Pac. J. Clin. Oncol.* 2012, 8, e55–e62. [CrossRef]

145. Horie, K.; Iseki, C.; Kikuchi, M.; Miyakawa, K.; Yoshizaki, M.; Yoshioka, H.; Watanabe, J. Bmi-1 Immunohistochemical Expression in Endometrial Carcinoma is Correlated with Prognostic Activity. *Medicina* 2020, 56, 72. [CrossRef]

146. Wang, X.; Wang, C.; Wang, L.; Du, L.; Wang, S.; Zheng, G.; Li, W.; Zhuang, X.; Zhang, X.; Dong, Z. Detection of circulating Bmi-1 mRNA in plasma and its potential diagnostic and prognostic value for uterine cervical cancer. *Int. J. Cancer* 2012, 131, 165–172. [CrossRef]

147. Cheng, J.; Dai, Y.; Liu, D.C.; Xue, C.; Zhu, H.; Liu, J.; Li, X.; Yu, X.; Wang, X.; Liu, Z.; et al. Telomerase activity is associated with BMI-1 expression in prostate cancer. *Ann. Diagn. Pathol.* 2014, 18, 58–62. [CrossRef] [PubMed]

148. Zhang, X.; Wang, C.; Wang, L.; Du, L.; Wang, S.; Zheng, G.; Li, W.; Zhuang, X.; Zhang, X.; Zhang, P.; et al. Detection of circulating Bmi-1 mRNA in plasma and its potential diagnostic and prognostic value for uterine cervical cancer. *Int. J. Cancer* 2012, 131, 165–172. [CrossRef] [PubMed]

149. Yi, C.; Li, B.B.; Zhou, C.X. Bmi-1 expression predicts prognosis in salivary adenoid cystic carcinoma and correlates with epithelial-mesenchymal transition-related factors. *Ann. Diagn. Pathol.* 2016, 22, 38–44. [CrossRef] [PubMed]
158. Allegra, E.; Puzzo, L.; Zuccalà, V.; Trapasso, S.; Vasquez, E.; Garozzo, A.; Caltabiano, R. Nuclear BMI-1 expression in laryngeal carcinoma correlates with lymph node pathological status. World J. Surg. Oncol. 2012, 10, 206. [CrossRef]

159. Song, W.; Tao, K.; Li, H.; Jin, C.; Song, Z.; Li, J.; Shi, H.; Li, X.; Dang, Z.; Dou, K. BMI-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci. 2010, 101, 1754–1760. [CrossRef]

160. Häyyr, V.; Mäkinen, L.K.; Atula, T.; Sariola, H.; Makitte, A.; Leivo, I.; Kesi-Säntti, H.; Lundin, J.; Haglund, C.; Hagström, J. BMI-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br. J. Cancer 2010, 102, 892–897. [CrossRef]

161. Lozneanu, L.; Balan, R.A.; Păvăleanu, I.; Giuscă, S.E.; Cărunu, I.D.; Amalinei, C. BMI-1 Expression Heterogeneity in Endometriosis-Related and Non-Endometriotic Ovarian Carcinoma. Int. J. Mol. Sci. 2021, 22, 6082. [CrossRef]

162. Cui, H.; Hu, B.; Li, T.; Ma, J.; Alam, G.; Gunnig, W.T.; Ding, H.F. BMI-1 is essential for the tumorigenicity of neuroblastoma cells. Am. J. Pathol. 2007, 170, 1370–1378. [CrossRef] [PubMed]

163. Farivar, S.; Zati Keikha, R.; Shiari, R.; Jadali, F. Expression of bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival. Biomed. Res. Int. 2013, 2013, 192548. [CrossRef]

164. Huber, G.F.; Albinger-Hegyi, A.; Söllermann, A.; Roessle, M.; Graf, N.; Haerle, S.K.; Holzmann, D.; Moch, H.; Hegyi, I. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer 2011, 117, 4659–4670. [CrossRef]

165. Mihic-Probst, D.; Kuster, A.; Kilgus, S.; Bode-Lesniewska, B.; Ingold-Heppner, B.; Leung, C.; Storz, M.; Seifert, B.; Marino, S.; Schraml, P.; et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer 2007, 121, 1764–1770. [CrossRef]

166. Yu, D.; Liu, Y.; Yang, J.; Jin, C.; Zhao, X.; Cheng, J.; Liu, X.; Qi, X. Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma. Cell Biochem. Biophys. 2015, 71, 261–269. [CrossRef] [PubMed]

167. Chen, Y.; Tian, G.; Ou, G.; Yang, K.; Chen, J.; Li, H.; Chen, S.; Li, J.; Zeng, L.; Huang, K. Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance. Gastric Cancer 2016, 19, 392–402. [CrossRef]

168. Dong, S.C.; Jing, R.N.; Pei, H.; Liu, F.; Zhao, B.X.; Meng, X.X. [Effect of Bmi-1 Expression on Chemotherapy Sensitivity in THP-1 Cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021, 29, 363–368. [CrossRef]

169. Herzog, A.E.; Warner, K.A.; Zhang, Z.; Bellile, E.; Bhagat, M.A.; Castilho, R.M.; Wolf, G.T.; Polverini, P.J.; Pearson, A.T.; Nör, J.E. Self-renewal as a therapeutic target in human colorectal cancer. Cell Stem Cell 2017, 20, 1199–1211. [CrossRef]

170. Bhattacharyya, J.; Mihara, K.; Ohtsubo, M.; Yasunaga, S.; Takei, Y.; Yanagihara, K.; Sakai, A.; Hoshi, M.; Takihara, Y.; Kimura, A. Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression. Cancer Sci. 2012, 103, 34–41. [CrossRef]

171. Wang, G.; Liu, L.; Sharma, S.; Liu, H.; Yang, W.; Sun, X.; Dong, Q. BMI-1 confers adaptive radioresistance to KYSE-150R esophageal carcinoma cells. Biochem. Biophys. Res. Commun. 2012, 425, 309–314. [CrossRef] [PubMed]

172. Jia, L.; Zhang, W.; Wang, C.Y. BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse. Cell Stem Cell 2020, 27, 238–253.e236. [CrossRef] [PubMed]

173. Kreso, A.; van Galen, P.; Pedley, N.M.; Lima-Fernandes, E.; Frelin, C.; Davis, T.; Cao, L.; Baiazitov, R.; Du, W.; Sydorenko, N.; et al. Targeting of BMI-1 with PTC-209 inhibits self-renewal as a therapeutic target in human colorectal cancer. Cell Stem Cell 2020, 261–269. [CrossRef] [PubMed]

174. Li, J.; Vangundy, Z.; Poi, M. PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines. Anticancer Res. 2020, 40, 133–141. [CrossRef] [PubMed]

175. Xu, J.; Zhang, Y.; Xu, J.; Wang, M.; Liu, G.; Wang, J.; Zhao, X.; Qi, Y.; Shi, J.; Cheng, K.; et al. Reversing tumor stemness via orally targeted nanoparticles achieves efficient colon cancer treatment. Biomaterials 2019, 216, 119247. [CrossRef]

176. Nishida, Y.; Maeda, A.; Kim, M.J.; Cao, L.; Kubota, Y.; Ishizawa, J.; Alrawi, A.; Kato, Y.; Iwama, A.; Fujisawa, M.; et al. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J. 2017, 7, e627. [CrossRef]

177. Maeda, A.; Nishida, Y.; Weetall, M.; Cao, L.; Bransstrom, A.; Ishizawa, J.; Nii, T.; Schober, W.D.; Abe, Y.; Matsue, K.; et al. Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma. Oncotarget 2018, 9, 28547–28560. [CrossRef] [PubMed]
183. Bolomsky, A.; Muller, J.; Stangelberger, K.; Lejeune, M.; Duray, E.; Breid, H.; Vrancken, L.; Pfeiffer, C.; Hübl, W.; Willheim, M.; et al. The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. Br. J. Haematol. 2020, 190, 877–890. [CrossRef] [PubMed]

184. Flamier, A.; Abdouh, M.; Hamann, R.; Barbino, A.; Patel, N.; Gao, A.; Hanna, R.; Bernier, G. Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme. NPJ Precis. Oncol. 2020, 4, 1. [CrossRef] [PubMed]

185. Jernigan, F.; Branstrom, A.; Baird, J.D.; Cao, L.; Dali, M.; Furia, B.; Kim, M.J.; O’Keefe, K.; Kong, R.; Laskin, O.L.; et al. Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent. Mol. Cancer Ther. 2021, 20, 1846–1857. [CrossRef] [PubMed]

186. Shapiro, G.I.; O’Mara, E.; Laskin, O.L.; Gao, L.; Baird, J.D.; Spiegel, R.J.; Kaushik, D.; Weetall, M.; Colacino, J.; O’Keefe, K.; et al. Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors. Clin. Pharmacol. Drug Dev. 2021, 10, 940–949. [CrossRef]

187. Bartucci, M.; Hussein, M.S.; Husseild, E.; Flaherty, K.; Patrizii, M.; Laddha, S.V.; Kui, C.; Bigos, R.A.; Gilleran, J.A.; El Ansary, M.M.S.; et al. Synthesis and Characterization of Novel BMI1 Inhibitors Characterizing Cell Self-Renewal in Hepatocellular Carcinoma. Target. Oncol. 2017, 12, 449–462. [CrossRef]

188. Dey, A.; Xiong, X.; Crim, A.; Dwivedi, S.K.D.; Mustafi, S.B.; Mukherjee, P.; Cao, L.; Sydorenko, N.; Biaizitrov, R.; Moon, Y.C.; et al. Evaluating the Mechanism and Therapeutic Potential of PTC-028, A Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol. Cancer Ther. 2018, 17, 39–49. [CrossRef]

189. Wang, J.; Xing, Y.; Wang, Y.; He, Y.; Wang, L.; Peng, S.; Yang, L.; Xie, J.; Li, X.; Qiu, W.; et al. A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal cancer. J. Exp. Clin. Cancer Res. 2019, 38, 422. [CrossRef]

190. Shields, C.E.; Potlapalli, S.; Cuya-Smith, S.M.; Chappell, S.K.; Chen, D.; Martinez, D.; Pogoriler, J.; Rathi, K.S.; Patel, S.A.; Oristian, K.M.; et al. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Mol. Oncol. 2021, 15, 2156–2171. [CrossRef]

191. Sulaiman, S.; Arafat, K.; Iratni, R.; Attoub, S. PTC-209 Anti-Cancer Effects Involved the Inhibition of STAT3 Phosphorylation. Front. Pharmacol. 2019, 10, 1199. [CrossRef]

192. Shan, W.; Zhou, L.; Li, L.; Liu, L.; Lin, D.; Yu, Q. Polycistrom group protein Bmi1 is required for the neuronal differentiation of mouse induced pluripotent stem cells. Exp. Ther. Med. 2021, 21, 619. [CrossRef] [PubMed]

193. Wang, X.; Li, K.; Cheng, M.; Wang, G.; Han, H.; Chen, F.; Liao, W.; Chen, Z.; Chen, J.; Bao, Y.; et al. Bmi1 Severs as a Potential Tumor-Initiating Cell Marker and Therapeutic Target in Esophageal Squamous Cell Carcinoma. Stem Cells Int. 2020, 2020, 8877577. [CrossRef] [PubMed]

194. Barbosa, K.; Deshpande, A.; Chen, B.R.; Ghosh, A.; Sun, Y.; Dutta, S.; Weetall, M.; Dixon, J.; Armstrong, S.A.; Bohlander, S.K.; et al. Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1. Exp. Hematol. 2019, 74, 42–51.e43. [CrossRef] [PubMed]

195. Ohtaka, M.; Itoh, M.; Toboda, S. BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells. Anticancer Res. 2017, 37, 6607–6603. [CrossRef] [PubMed]

196. Nishida, Y.; Maeda, A.; Chachad, D.; Ishizawa, J.; Qiu, Y.H.; Kornblau, S.M.; Kimura, S.; Andreeff, M.; Kojima, K. Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapy. Cancer Sci. 2015, 106, 1705–1713. [CrossRef] [PubMed]

197. Dimri, M.; Kang, M.; Dimri, G.P. A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells. Oncotarget 2016, 7, 36220–36234. [CrossRef]

198. Mayr, C.; Wagner, A.; Loeﬂelberger, M.; Bruckner, D.; Jakab, M.; Berr, F.; Di Fazio, P.; Ocker, M.; Neureiter, D.; Pichler, M.; et al. The BMI1 inhibitor PTC-209 is a potent compound to halt cellular growth in biliary tract cancer cells. Oncotarget 2019, 7, 745–758. [CrossRef] [PubMed]

199. Nagai, Y.; Mimura, N.; Rizq, O.; Ishii, Y.; Oshima, M.; Rizk, M.; Saraya, A.; Koide, S.; Nakajima-Takagi, Y.; Miyota, M.; et al. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Sci Rep. 2021, 11, 2074. [CrossRef]

200. Eberle-Singh, J.A.; Sagalovskiy, I.; Maurer, H.C.; Sastra, S.A.; Olive, K.P. Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2019, 25, 5548–5560. [CrossRef]

201. Kumar, S.S.; Sengupta, S.; Zhu, X.; Mishra, D.K.; Phoenix, T.; Dyer, L.; Fuller, C.; Stevenson, C.B.; Dewire, M.; Fouladi, M. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation. Mol. Cancer Res. 2020, 18, 1711–1723. [CrossRef] [PubMed]

202. Balakrishnan, I.; Danis, E.; Pierce, A.; Madhavan, K.; Wang, D.; Dahl, N.; Sanford, B.; Birks, D.K.; Davidson, N.; Metselaar, D.S.; et al. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG. Cell Rep. 2020, 33, 10826. [CrossRef]

203. Bakhshinyan, D.; Venugopal, C.; Adile, A.A.; Garg, N.; Manoranjan, B.; Hallett, R.; Wang, X.; Mahendram, S.; Vora, P.; Vijaykumar, T.; et al. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene 2019, 38, 1702–1716. [CrossRef] [PubMed]

204. Buechel, M.; Dey, A.; Dwivedi, S.K.D.; Crim, A.; Ding, K.; Zhang, R.; Mukherjee, P.; Moore, K.N.; Cao, L.; Branstorn, A.; et al. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol. Cancer Ther. 2018, 17, 2136–2143. [CrossRef]
205. Yang, L.F.; Xing, Y.; Xiao, J.X.; Xie, J.; Gao, W.; Xie, J.; Wang, L.T.; Wang, J.; Liu, M.; Yi, Z.; et al. Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents. *ACS Med. Chem. Lett.* 2018, 9, 1105–1110. [CrossRef]

206. Wu, J.; Hu, D.; Yang, G.; Zhou, J.; Yang, C.; Gao, Y.; Zhu, Z. Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells. *J. Cell Biochem.* 2011, 112, 1938–1948. [CrossRef]

207. Wang, Y.Y.; Yang, Y.X.; Zhao, R.; Pan, S.T.; Zhe, H.; He, Z.X.; Duan, W.; Zhang, X.; Yang, T.; Qiu, J.X.; et al. Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells. *Drug Des. Dev. Ther.* 2015, 9, 993–1026. [CrossRef]

208. Zhao, Z.; Yang, Y.; Zeng, Y.; He, M. A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis. *Lab Chip* 2016, 16, 489–496. [CrossRef]

209. Glia, A.; Deliorman, M.; Sukumar, P.; Janahi, F.K.; Samara, B.; Brimmo, A.T.; Qasaimeh, M.A. Herringbone Microfluidic Probe for Multiplexed Affinity-Capture of Prostate Circulating Tumor Cells. *Adv. Mater. Technol.* 2021, 6, 2100053. [CrossRef]

210. Kure, K.; Hosoya, M.; Ueyama, T.; Fukaya, M.; Komiyama, H. Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer. *Oncol. Lett.* 2020, 19, 2286–2294. [CrossRef]